These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34427069)

  • 21. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
    McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
    J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.
    Genant HK; Engelke K; Bolognese MA; Mautalen C; Brown JP; Recknor C; Goemaere S; Fuerst T; Yang YC; Grauer A; Libanati C
    J Bone Miner Res; 2017 Jan; 32(1):181-187. PubMed ID: 27487526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.
    Kaveh S; Hosseinifard H; Ghadimi N; Vojdanian M; Aryankhesal A
    Clin Rheumatol; 2020 Nov; 39(11):3261-3276. PubMed ID: 32385757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Maddox J; Shi Y; Rojeski M; Meisner PD; Grauer A
    Osteoporos Int; 2020 Nov; 31(11):2231-2241. PubMed ID: 32623487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis.
    Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
    Clin Nutr ESPEN; 2022 Apr; 48():267-274. PubMed ID: 35331501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial.
    Eriksen EF; Chapurlat R; Boyce RW; Shi Y; Brown JP; Horlait S; Betah D; Libanati C; Chavassieux P
    J Bone Miner Res; 2022 Jan; 37(1):36-40. PubMed ID: 34633116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Romosozumab : a new treatment for severe osteoporosis].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2021 Apr; 17(735):784-787. PubMed ID: 33881241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Romosozumab: a novel bone anabolic treatment option for osteoporosis?
    Kerschan-Schindl K
    Wien Med Wochenschr; 2020 Apr; 170(5-6):124-131. PubMed ID: 31858345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonresponder Considerations for Romosozumab Treatment.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Shimamoto S; Kodama Y; Kato Y
    Calcif Tissue Int; 2023 Aug; 113(2):157-165. PubMed ID: 37138124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skeletal responses to romosozumab after 12 months of denosumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Shi Y; Timoshanko J; Libanati C; Chines A; Oates MK
    JBMR Plus; 2021 Jul; 5(7):e10512. PubMed ID: 34258507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A; Zerbini CA; Milmont CE; Chen L; Maddox J; Meisner PD; Libanati C; Grauer A
    N Engl J Med; 2016 Oct; 375(16):1532-1543. PubMed ID: 27641143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
    N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study.
    Inose H; Kato T; Tomizawa S; Ariga A; Motoyoshi T; Fukushima K; Takahashi K; Yoshii T; Okawa A
    Bone Rep; 2022 Dec; 17():101635. PubMed ID: 36389625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
    Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
    Cosman F; Crittenden DB; Ferrari S; Khan A; Lane NE; Lippuner K; Matsumoto T; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2018 Jul; 33(7):1219-1226. PubMed ID: 29573473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A; Swe KM; Sinha NK; Osunkwo I
    Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.